Cargando…

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain

PURPOSE: Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Crépey, Pascal, Redondo, Esther, Díez-Domingo, Javier, Ortiz de Lejarazu, Raúl, Martinón-Torres, Federico, Gil de Miguel, Ángel, López-Belmonte, Juan Luis, Alvarez, Fabián P., Bricout, Hélène, Solozabal, Míriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241783/
https://www.ncbi.nlm.nih.gov/pubmed/32437476
http://dx.doi.org/10.1371/journal.pone.0233526
_version_ 1783537128444002304
author Crépey, Pascal
Redondo, Esther
Díez-Domingo, Javier
Ortiz de Lejarazu, Raúl
Martinón-Torres, Federico
Gil de Miguel, Ángel
López-Belmonte, Juan Luis
Alvarez, Fabián P.
Bricout, Hélène
Solozabal, Míriam
author_facet Crépey, Pascal
Redondo, Esther
Díez-Domingo, Javier
Ortiz de Lejarazu, Raúl
Martinón-Torres, Federico
Gil de Miguel, Ángel
López-Belmonte, Juan Luis
Alvarez, Fabián P.
Bricout, Hélène
Solozabal, Míriam
author_sort Crépey, Pascal
collection PubMed
description PURPOSE: Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain. METHODS: A dynamic transmission model was developed to estimate the number of influenza B cases prevented under TIV and QIV strategies (<65 years (high risk) and ≥65 years). This model considers cross-protective immunity induced by different lineages of influenza B. The output of the transmission model was used as input for a decision tree model that estimated the economic impact of switching TIV to QIV. The models were populated with Spanish data whenever possible. Deterministic univariate and probabilistic multivariate sensitivity analyses were performed. RESULTS: Replacing TIV with QIV in all eligible patients with current vaccine coverage in Spain may have prevented 138,707 influenza B cases per season and, therefore avoided 10,748 outpatient visits, 3,179 hospitalizations and 192 deaths. The replacement could save €532,768 in outpatient visit costs, €13 million in hospitalization costs, and €3 million in costs of influenza-related deaths per year. An additional €5 million costs associated with productivity loss could be saved per year, from the societal perspective. The budget impact from societal perspective would be €6.5 million, and the incremental cost-effectiveness ratio (ICER) €1,527 per quality-adjusted life year (QALY). Sensitivity analyses showed robust results. In additional scenarios, QIV also showed an impact at public health level reducing influenza B related cases, outpatient visits, hospitalizations and deaths. CONCLUSIONS: Our results show public health and economic benefits for influenza prevention with QIV. It would be an efficient intervention for the Spanish National Health Service with major health benefits especially in the population ≥65-year.
format Online
Article
Text
id pubmed-7241783
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-72417832020-06-03 From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain Crépey, Pascal Redondo, Esther Díez-Domingo, Javier Ortiz de Lejarazu, Raúl Martinón-Torres, Federico Gil de Miguel, Ángel López-Belmonte, Juan Luis Alvarez, Fabián P. Bricout, Hélène Solozabal, Míriam PLoS One Research Article PURPOSE: Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain. METHODS: A dynamic transmission model was developed to estimate the number of influenza B cases prevented under TIV and QIV strategies (<65 years (high risk) and ≥65 years). This model considers cross-protective immunity induced by different lineages of influenza B. The output of the transmission model was used as input for a decision tree model that estimated the economic impact of switching TIV to QIV. The models were populated with Spanish data whenever possible. Deterministic univariate and probabilistic multivariate sensitivity analyses were performed. RESULTS: Replacing TIV with QIV in all eligible patients with current vaccine coverage in Spain may have prevented 138,707 influenza B cases per season and, therefore avoided 10,748 outpatient visits, 3,179 hospitalizations and 192 deaths. The replacement could save €532,768 in outpatient visit costs, €13 million in hospitalization costs, and €3 million in costs of influenza-related deaths per year. An additional €5 million costs associated with productivity loss could be saved per year, from the societal perspective. The budget impact from societal perspective would be €6.5 million, and the incremental cost-effectiveness ratio (ICER) €1,527 per quality-adjusted life year (QALY). Sensitivity analyses showed robust results. In additional scenarios, QIV also showed an impact at public health level reducing influenza B related cases, outpatient visits, hospitalizations and deaths. CONCLUSIONS: Our results show public health and economic benefits for influenza prevention with QIV. It would be an efficient intervention for the Spanish National Health Service with major health benefits especially in the population ≥65-year. Public Library of Science 2020-05-21 /pmc/articles/PMC7241783/ /pubmed/32437476 http://dx.doi.org/10.1371/journal.pone.0233526 Text en © 2020 Crépey et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Crépey, Pascal
Redondo, Esther
Díez-Domingo, Javier
Ortiz de Lejarazu, Raúl
Martinón-Torres, Federico
Gil de Miguel, Ángel
López-Belmonte, Juan Luis
Alvarez, Fabián P.
Bricout, Hélène
Solozabal, Míriam
From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title_full From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title_fullStr From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title_full_unstemmed From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title_short From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
title_sort from trivalent to quadrivalent influenza vaccines: public health and economic burden for different immunization strategies in spain
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241783/
https://www.ncbi.nlm.nih.gov/pubmed/32437476
http://dx.doi.org/10.1371/journal.pone.0233526
work_keys_str_mv AT crepeypascal fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT redondoesther fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT diezdomingojavier fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT ortizdelejarazuraul fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT martinontorresfederico fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT gildemiguelangel fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT lopezbelmontejuanluis fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT alvarezfabianp fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT bricouthelene fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain
AT solozabalmiriam fromtrivalenttoquadrivalentinfluenzavaccinespublichealthandeconomicburdenfordifferentimmunizationstrategiesinspain